Compare · FRNM vs GRAL
FRNM vs GRAL
Side-by-side comparison of Freenome Inc. (FRNM) and GRAIL Inc. (GRAL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRNM and GRAL operate in Medical Specialities (Health Care), so they compete in similar markets.
- GRAL is the larger of the two at $5.21B, about 4.5x FRNM ($1.16B).
- GRAL has been more active in the news (7 items in the past 4 weeks vs 3 for FRNM).
- GRAL has more recent analyst coverage (14 ratings vs 0 for FRNM).
- Company
- Freenome Inc.
- GRAIL Inc.
- Price
- -
- -
- Market cap
- $1.16B
- $5.21B
- 1M return
- -15.06%
- -
- 1Y return
- -3.52%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 7
- Recent ratings
- 0
- 14
FRNM
Freenome Inc.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's development of SimpleScreen CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals.
Latest FRNM
Latest GRAL
- SEC Form SCHEDULE 13G filed by GRAIL Inc.
- SEC Form 10-Q filed by GRAIL Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.
- GRAIL Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- GRAIL Reports Third Quarter 2026 Financial Results
- GRAIL to Present at the UBS Global Healthcare Conference
- GRAIL to Announce Third Quarter 2026 Financial Results
- SEC Form 4 filed by GRAIL Inc.
- SEC Form 4 filed by GRAIL Inc.
- SEC Form 4 filed by GRAIL Inc.